Sign in Subscribe

article

A collection of 632 issues

Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China

Skip to content The CRC Digest Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China (Frontiers in Pharmacology) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Longitudinal toxicity analysis reveals chronic burden of cetuximab in metastatic colorectal cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Longitudinal toxicity analysis reveals chronic burden of cetuximab in metastatic colorectal cancer A pooled analysis of 1,302 patients from the ARCAD database applied a longitudinal toxicity framework to compare chemotherapy with or without cetuximab, finding that traditional single worst-grade reporting

New model suggests accelerated colorectal carcinogenesis may limit screening effectiveness

Skip to content The CRC Digest ▪ SCREENING New model suggests accelerated colorectal carcinogenesis may limit screening effectiveness Researchers propose an exposure-driven accelerated carcinogenesis model to explain rising early-onset CRC, increasing distal and rectal tumors, and post-colonoscopy CRC despite high-quality screening, suggesting that current slowly progressive models may not fully capture

HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases

Skip to content The CRC Digest ▸ TREATMENT HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases An updated meta-analysis of 12 studies (including 2 randomized controlled trials) encompassing more than 2,700 patients found that hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic therapy

Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer A study examined dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H metastatic colorectal cancer, reporting early survival benefit and exploratory clinical predictors. (Clinical Colorectal Cancer) This content is

Ifebemtinib plus garsorasib shows activity in KRAS G12C-mutated metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Ifebemtinib plus garsorasib shows activity in KRAS G12C-mutated metastatic colorectal cancer A phase 1b/2 trial tested the combination of ifebemtinib (a focal adhesion kinase inhibitor) with garsorasib (a KRAS G12C inhibitor) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer.

Blood-Based Screening Now Available Starting at Age 45

Skip to content The CRC Digest Blood-Based Screening Now Available Starting at Age 45 The newly FDA-approved SimpleScreen CRC blood test is available for adults aged 45 years and older who are at average risk for colorectal cancer. (The ASCO Post) This content is informational only and does not constitute

ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery

Skip to content The CRC Digest ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer

Risk-Adapted Screening Strategy Shows Promise for Early-Onset CRC

Skip to content The CRC Digest ▪ SCREENING Risk-Adapted Screening Strategy Shows Promise for Early-Onset CRC A new study found that implementing a RAP-based risk-adapted screening strategy enables personalized screening initiation, with benefits comparable to those observed in the current 50-54-year age group. (Cancer Science) This content is informational only and

Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC A phase Ib/II study (NCT05176665) of EMB-01, a novel EGFR × c-MET bispecific antibody, enrolled 52 patients with heavily pretreated metastatic colorectal cancer. EMB-01 was administered at 1600 mg intravenously weekly, with primary